Skip to main content

Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer

Active, not recruiting · Phase 3 · NCT03155997

Conditions: Breast Cancer

At a glance

Research payments reported, 2025
$789,401
U.S. investigators named
103
Sites paid
106
Planned or actual enrollment
5,637

About the trial

Sponsor
Eli Lilly and Company (with NSABP Foundation Inc)
Tested
Abemaciclib (drug), Standard Adjuvant Endocrine Therapy (drug)
Dates
Started 2017-07-12; completion 2029-05
Results posted
Yes

The purpose of this study is to evaluate the safety and efficacy of the study drug abemaciclib in participants with high risk, node positive, early stage, hormone receptor positive (HR+), human epidermal receptor 2 negative (HER2-), breast cancer.

From ClinicalTrials.gov, last updated 2026-04-24. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Eli Lilly and Company reported $789,401 in research payments for this study in 2025 (157 payments).

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.